BTI BiOasis Technologies Inc

biOasis Technologies, Inc. (TSX VENTURE:BTI)(OTCBB:BIOAF), a pioneer in the
delivery of therapeutics across the blood-brand barrier, has engaged Liolios
Group to lead a new investor relations and financial communications campaign.


"Over the course of the last 12 months, leading independent researchers have
demonstrated how our Transcend(TM) technology is able to overcome one of
greatest challenges in modern medicine: effectively delivering therapeutic drugs
across the blood brain barrier in animal models," said Rob Hutchison, chief
executive officer and founder of biOasis. "Now with our technology receiving
notice of issuance of its 31st patent earlier this month, we are moving forward
with initiatives to license this breakthrough technology to major players in the
pharmaceutical industry for whom it can expand the indication of a wide range of
approved and research therapeutics and to potentially extend their patent life."


"Given these compelling factors, we believe the time has come to engage an
experienced U.S. team of investor relations professionals to help us communicate
our story to the financial community," continued Hutchison. "Liolios Group
brings a proven track record of helping companies like biOasis enhance its
shareholder value by delivering the right message to the right audience and
building high quality, long-term relationships in the investment community." 


Liolios Group will work closely with biOasis's management to refine and deliver
the company's message and make introductions to key investors and influencers in
the financial community. They will also assist the company in scheduling road
shows and financial conferences over the next several months.


The initial term of the engagement is six months that will be automatically
renewed for successive three month periods unless either party shall notify the
other in writing of its intention not to renew the engagement. Over the initial
term of the agreement, Liolios will be paid a monthly retainer for the first
three months of $8,000 and for the second three months, $7,000. In addition,
Liolios will be granted 200,000 options priced at $1.07 with a term of one year.
The stock options will vest in stages over a period of 12 months, with 50,000
options vesting three months after the date of grant and 50,000 vesting each
three months thereafter. This investor relations contract and options grant and
terms are subject to the approval of the TSX Venture Exchange. 


To arrange for a call or meeting with management, contact Justin Vaicek at (949)
574-3860 or justin@liolios.com.


About Liolios Group

Liolios Group is a highly selective and comprehensive investor relations firm
specializing in micro to mid-cap companies. The firm aims to deliver superior
performance in corporate messaging and positioning, investor awareness, analyst
and financial press coverage and capital attraction. Founded in 1999, Liolios
Group executives have extensive experience in financial and investments and
represent clients in a wide range of industries, including life
sciences/healthcare, consumer/internet retail, business services, digital,
media/software, clean technology, technology, natural resources and special
situations. 


For more information about Liolios Group, visit www.liolios.com.

About Bioasis

biOasis Technologies Inc. is a biopharmaceutical company headquartered in
Vancouver, Canada. Based on Transcend, biOasis proprietary brain delivery
platform, the Company is focused on creating new drugs that can cross the
blood-brain barrier to address unmet medical needs in the treatment of brain
diseases such as neurodegeneration, metastatic cancer and metabolic diseases.
biOasis trades on the TSX Venture Exchange under the symbol "BTI". For more
information about the Company please visit www.bioasis.ca.


Forward-Looking Statements

Certain statements in this press release contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities legislation
that may not be based on historical fact, including without limitation
statements containing the words "believe", "may", "plan", "will", "estimate",
"continue", "anticipate", "intend", "expect" and similar expressions. Such
forward-looking statements or information involve known and unknown risks,
uncertainties and other factors that may cause our actual results, events or
developments, or industry results, to be materially different from any future
results, events or developments express or implied by such forward-looking
statements or information. Such factors include, among others, our stage of
development, lack of any product revenues, additional capital requirements, risk
associated with the completion of clinical trials and obtaining regulatory
approval to market our products, the ability to protect our intellectual
property, dependence on collaborative partners and the prospects for negotiating
additional corporate collaborations or licensing arrangements and their timing.
Specifically, certain risks and uncertainties that could cause such actual
events or results expressed or implied by such forward-looking statements and
information to differ materially from any future events or results expressed or
implied by such statements and information include, but are not limited to, the
risks and uncertainties that: we may not be able to successfully develop and
obtain regulatory approval for p97 as a Physician's Aid to Diagnose Alzheimer's,
or future products in our targeted corporate objectives; our future operating
results are uncertain and likely to fluctuate; we may not be able to raise
additional capital; we may not be successful in establishing additional
corporate collaborations or licensing arrangements; we may not be able to
establish marketing and the costs of launching our products may be greater than
anticipated; we have no experience in commercial manufacturing; we may face
unknown risks related to intellectual property matters; we face increased
competition from pharmaceutical and biotechnology companies; and other factors
as described in detail in our filings with the Canadian securities regulatory
authorities at www.sedar.com. Given these risks and uncertainties, you are
cautioned not to place undue reliance on such forward-looking statements and
information, which are qualified in their entirety by this cautionary statement.
All forward-looking statements and information made herein are based on our
current expectations and we undertake no obligation to revise or update such
forward- looking statements and information to reflect subsequent events or
circumstances, except as required by law.


On Behalf of the Board of Directors 

Rob Hutchison, Chairman & CEO 

"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release".


FOR FURTHER INFORMATION PLEASE CONTACT: 
biOasis Technologies Inc.
Rob Hutchison
Chairman & CEO
(778).383.3280
rob@bioasis.ca
www.bioasis.ca


Liolios Group
Justin Vaicek
Investor Relations
(949).574.3860
BTI@liolios.com

Grafico Azioni BiOasis Technologies (TSXV:BTI)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni BiOasis Technologies (TSXV:BTI)
Storico
Da Giu 2023 a Giu 2024